- Companies
- Avenue Therapeutics
Avenue Therapeutics Valuation Multiples
Avenue Therapeutics is valued at $988K as of November 2026. In the last fiscal year, Avenue Therapeutics revenue was $1M and Avenue Therapeutics EBITDA was ($3M).
Avenue Therapeutics Overview
About Avenue Therapeutics
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its current product candidates include AJ201 for the treatment of spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's Disease), intravenous tramadol (IV tramadol) for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders.
Founded
2015
HQ
Employees
2
Website
Sectors
Financials (Last FY)
Market Cap
$988K
Valuation Multiples
Start free trialAvenue Therapeutics Financials
Avenue Therapeutics reported last fiscal year revenue of $1M and negative EBITDA of ($3M).
In the same fiscal year, Avenue Therapeutics generated ($3M) in EBITDA losses and had net loss of ($3M).
Avenue Therapeutics P&L
In the most recent fiscal year, Avenue Therapeutics reported revenue of $1M and EBITDA of ($3M).
Avenue Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of (219%) and net margin of (207%).
Financial data powered by Morningstar, Inc.
Avenue Therapeutics Stock Performance
Avenue Therapeutics has current market cap of $988K.
Market Cap Evolution
Avenue Therapeutics' stock price is $0.30.
Avenue Therapeutics has an EPS (earnings per share) of $-0.88.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $988K | 7.1% | - | - | - | $-0.88 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAvenue Therapeutics Valuation Multiples
Avenue Therapeutics Financial Valuation Multiples
As of November 19, 2026, Avenue Therapeutics has market cap of $988K.
Avenue Therapeutics has a P/E ratio of (0.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Avenue Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Avenue Therapeutics Margins & Growth Rates
In the most recent fiscal year, Avenue Therapeutics reported EBITDA margin of (219%) and net margin of (207%).
Avenue Therapeutics Margins
Data powered by FactSet, Inc. and Morningstar, Inc.
Avenue Therapeutics Operational KPIs
Avenue Therapeutics' revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $2.2M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Avenue Therapeutics Competitors
Avenue Therapeutics competitors include Bone Biologics, Matinas BioPharma Holdings, Cannovum Cannabis, Silexion Therapeutics, Biodexa Pharmaceuticals, Geovax Labs, Gabather, Respiratorius, RAMM Pharma and Karyopharm Therapeutics.
Most Avenue Therapeutics public comparables operate across Biopharmaceuticals and BioTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | ($3M) | - | - | - | - | |||
| - | ($10M) | - | - | (0.0x) | - | |||
| - | ($447K) | - | - | (2.1x) | - | |||
| - | ($12M) | - | - | - | - | |||
| - | ($8M) | - | - | - | - | |||
| $2M | ($22M) | - | - | - | - | |||
| - | ($446K) | - | - | (1.7x) | (1.6x) | |||
| - | ($350K) | - | - | (3.2x) | - | |||
This data is available for Pro users. Sign up to see all Avenue Therapeutics competitors and their valuation data. Start Free Trial | ||||||||
Avenue Therapeutics VC Funding History
Before going public, Avenue Therapeutics raised $35M in total equity funding, across 1 round.
Last private valuation of Avenue Therapeutics was $105M, after raising $35M in November 2018 from Cipla.
Avenue Therapeutics Funding Rounds
Acquisitions by Avenue Therapeutics
Avenue Therapeutics has acquired 1 company to date.
Last acquisition by Avenue Therapeutics was on November 8th 2022. Avenue Therapeutics acquired Baergic Bio for undisclosed valuation.
Latest Acquisitions by Avenue Therapeutics
| Description | Baergic Bio is a clinical-stage biopharmaceutical company based in New York that develops BAER-101, an oral GABA-A alpha 2/3 receptor modulator licensed from AstraZeneca for central nervous system disorders. Avenue Therapeutics acquired it from Fortress Biotech in 2022. |
| HQ Country | |
| HQ City | New York City, NY |
| Deal Date | 8 Nov 2022 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Avenue Therapeutics acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Avenue Therapeutics
| When was Avenue Therapeutics founded? | Avenue Therapeutics was founded in 2015. |
| Where is Avenue Therapeutics headquartered? | Avenue Therapeutics is headquartered in United States. |
| How many employees does Avenue Therapeutics have? | As of today, Avenue Therapeutics has over 2 employees. |
| Is Avenue Therapeutics publicly listed? | Yes, Avenue Therapeutics is a public company listed on OTCM. |
| What is the stock symbol of Avenue Therapeutics? | Avenue Therapeutics trades under ATXI ticker. |
| When did Avenue Therapeutics go public? | Avenue Therapeutics went public in 2017. |
| Who are competitors of Avenue Therapeutics? | Avenue Therapeutics main competitors include Bone Biologics, Matinas BioPharma Holdings, Cannovum Cannabis, Silexion Therapeutics, Biodexa Pharmaceuticals, Geovax Labs, Gabather, Respiratorius, RAMM Pharma, Karyopharm Therapeutics. |
| What is the current market cap of Avenue Therapeutics? | Avenue Therapeutics' current market cap is $988K. |
| What is the current revenue of Avenue Therapeutics? | Avenue Therapeutics' last fiscal year revenue is $1M. |
| Is Avenue Therapeutics profitable? | No, Avenue Therapeutics is not profitable. |
| How many companies Avenue Therapeutics has acquired to date? | As of November 2026, Avenue Therapeutics has acquired 1 company. |
| What was the largest acquisition by Avenue Therapeutics? | None of the M&A deals Avenue Therapeutics has completed have disclosed valuations. |
| What companies Avenue Therapeutics acquired? | Avenue Therapeutics acquired Baergic Bio. |
| In how many companies Avenue Therapeutics has invested to date? | Avenue Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Avenue Therapeutics
Lists including Avenue Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




